NanoSol is a technology for the production of nano-sized drug particles. Formulation of a drug substance in nano-particle form significantly increases the surface area available for dissolution. A ten-to-twenty-fold increase in surface area can result from reducing particle size from a micronized drug substance to a nanonized drug substance.
As surface area increases, the rate of dissolution increases and bioavailability improvements may result. If a solid dosage form is desired, the nano-particles are stabilized by adsorption onto polymer carriers – a process conducted by fluid bed coating. Alternatively, the nano-particles can be prepared as a suspension and administered as a liquid – either orally or by injection.
Ascendia uses a bead-milling process for production of nano-particles, and can investigate the impact of nanonization with small amounts of drug substance. Ascendia’s nano-particle technology can enable pharmaceutical products with enhanced bioavailability, reduced food-effect and more rapid onset-of-action.
Dissolution of poorly soluble drugs can be further improved by formulating the nano-particle as a homogenous mixture of the drug and a lipophilic excipient. By combining the drug with a lipid carrier, the energy required for the drug to dissolve in the body is greatly lowered.
CASE STUDY – ASD-005
ASD-005 is a weakly basic cardiovascular drug with a low solubility in aqueous media. Currently it is only available as an oral dosage form. An injectable nano-particle formulation was developed for use in an acute care setting. The drug substance in nanoparticle form is stabilized using lipid excipients to enhance the drug loading and to achieve a sustained release in vivo. The process involves the homogenous mixture of drug and lipids, and nano-sizing in a parenteral grade vehicle. Three prototype formulations were prepared with different drug loadings (drug weight/solution volume). The table shows the nano-particle size and drug loading for the three formulations.
The figure shows the morphology of the lipid nano-particles.
A sustained release PK profile with a enhanced bioavailability was achieved in an animal study over a 24 hour period following IV injection of the nano-particle formulation.
Ascendia specializes in the application of nano-technology approaches to develop novel pharmaceutical products. Our suite of state-of-the-art technologies for formulating poorly water soluble compounds provides sophisticated formulation options for our clients. Contact us today for more information on how our formulations can enable your pharmaceutical product.
Want to learn more about
Get up-to-date information